NCT06483737View on ClinicalTrials.gov

Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE)

NARecruitingINTERVENTIONAL

Enrollment

174

Participants

Timeline

Start Date

June 24, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions

Overt Hepatic Encephalopathy

Interventions

DRUG

Human albumin infusion at a modified dosage

Participants receive intravenous infusion of human albumin at different dosages according to the serum albumin level.

DRUG

Human albumin infusion at a routine dosage

Participants receive intravenous infusion of human albumin according to the current clinical practice.

DRUG

Lactulose

All participants will receive standard treatment of overt HE according to the current practice guideline.

DRUG

Rifaximin

All participants will receive standard treatment of overt HE according to the current practice guideline.

DRUG

Ornithine Aspartate

All participants will receive standard treatment of overt HE according to the current practice guideline.

DRUG

Branched-Chain Amino Acids

All participants will receive standard treatment of overt HE according to the current practice guideline.

DRUG

Arginine

All participants will receive standard treatment of overt HE according to the current practice guideline.

Trial Locations (1)

Unknown

RECRUITING

Department of Gastroenterology, General Hospital of Northern Theater Command (formerly called General Hospital of Shenyang Military Area), Shenyang

All Listed Sponsors

lead

General Hospital of Shenyang Military Region

OTHER

NCT06483737 - Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE) | Biotech Hunter | Biotech Hunter